$RVMD · Revolution Medicines, Inc. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for Revolution Medicines, Inc. ($RVMD) from November 5, 2026 through November 5, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$RVMD 8-K — Revolution Medicines, Inc.
A $197.6M partial-quarter launch for a first-in-class pancreatic cancer drug validates the commercial thesis and signals rapid market uptake.
$RVMD 10-Q — Revolution Medicines, Inc.
First commercial revenue from RASONQUE validates the company's transition to a revenue-generating oncology player despite a widening net loss.